WGSGeneDx Holdings Corp.

$3B

Q3 2024 Earnings

Healthcare Medical - Healthcare Information Services

Income Statement

Revenue

$77M+44.2% YoY

Gross Profit

$48M62.2% margin

Operating Income

-$8M-10.1% margin

Net Income

-$8M-10.8% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+9.0%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$409M

Total Liabilities

$204M

Stockholders' Equity

$205M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$53M	+44.2%
Gross Profit	$48M	$25M	+89.4%
Operating Income	-$8M	-$43M	+81.9%
Net Income	-$8M	-$42M	+80.3%

Revenue Segments

Diagnostic Test

$77M50%

Diagnostic Test, Third Party Insurance

$60M38%

Diagnostic Test, Institutional Customers

$17M11%

Diagnostic Test, Self Pay

$460,0000%

WGS Q3 2024 Earnings — GeneDx Holdings Corp. Revenue & Financial Results | Market Cap Arena